[1] |
Shallis RM, Zeidan AM, Wang R, et al. Epidemiology of the Philadelphia chromosome-negative classical myeloproliferative neoplasms [J]. Hematol Oncol Clin North Am, 2021, 35(2): 177-189.
|
[2] |
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J]. Blood, 2016, 127(20): 2391-2405.
|
[3] |
Fujita K, Hatta K. Renal biopsy cases in myeloproliferative neoplasms (MPN) [J]. CEN Case Rep, 2013, 2(2): 215-221.
|
[4] |
Au WY, Chan KW, Lui SL, et al. Focal segmental glomerulosclerosis and mesangial sclerosis associated with myeloproliferative disorders [J]. Am J Kidney Dis, 1999, 34(5): 889-893.
|
[5] |
Asaba K, Tojo A, Onozato ML, et al. Fibrillary glomerulonephritis associated with essential thrombocytosis [J]. Clin Exp Nephrol, 2003, 7(4): 296-300.
|
[6] |
Said SM, Leung N, Sethi S, et al. Myeloproliferative neoplasms cause glomerulopathy [J]. Kidney Int, 2011, 80(7): 753-759.
|
[7] |
Haraguchi K, Shimura H, Ogata R, et al. Focal segmental glomerulosclerosis associated with essential thrombocythemia [J]. Clin Exp Nephrol, 2006, 10(1): 74-77.
|
[8] |
Saigusa T, Kikuchi Y, Yamada M, et al. A case of essential thrombocytosis developing nephrotic syndrome and severe endothelial damage [J]. J Nephrol, 2006, 19(5): 656-659.
|
[9] |
Alexander MP, Nasr SH, Kurtin PJ, et al. Renal extramedullary hematopoiesis: interstitial and glomerular pathology [J]. Mod Pathol, 2015, 28(12): 1574-1583.
|
[10] |
Bardy A, Tiple A, Rabant M, et al. The myeloproliferative neoplasms-related glomerulopathy [J]. Rev Med Interne, 2014, 35(4): 222-230.
|
[11] |
Rahimian S, Johnson T, Herb R. A case of essential thrombocythemia and IgA nephropathy with literature review of the concurrence [J]. Case Rep Oncol Med, 2019, 2019: 5086963.
|
[12] |
Büttner-Herold M, Sticht C, Wiech T, et al. Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms [J]. Histopathology, 2021, 78(5): 738-748.
|
[13] |
王彦,薛新萍,谭会斌,等. 原发性血小板增多症并发膜性肾病一例[J]. 中华肾脏病杂志,2010, 26(11): 871.
|
[14] |
Suzuki H, Yasutake J, Makita Y, et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis [J]. Kidney Int, 2018, 93(3): 700-705.
|
[15] |
Tefferi A, Pardanani A. Essential thrombocythemia [J]. N Engl J Med, 2019, 381(22): 2135-2144.
|
[16] |
Makita Y, Arakawa T, Masaki T, et al. Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis[J]. Nephrol Dial Transplant, 2008, 23(11): 3418-3426.
|
[17] |
Yamada K, Huang ZQ, Raska M, et al. Inhibition of STAT3 signaling reduces IgA1 autoantigen production in IgA nephropathy[J]. Kidney Int Rep, 2017, 2(6): 1194-1207.
|
[18] |
Xiao J, Wang M, Xiong D, et al. TGF-β1 mimics the effect of IL-4 on the glycosylation of IgA1 by downregulating core 1 β1, 3-galactosyltransferase and Cosmc [J]. Mol Med Rep, 2017, 15(2): 969-974.
|
[19] |
Bian Q, Anderson JC, Zhang XW, et al. Mesangioproliferative kidney diseases and platelet-derived growth factor-mediated AXL phosphorylation [J]. Kidney Med, 2021, 3(6): 1003-1013.
|
[20] |
Cai A, Chatziantoniou C, Calmont A. Vascular permeability: regulation pathways and role in kidney diseases [J]. Nephron, 2021, 145(3): 297-310.
|
[21] |
Kwiatkowski J, Kuliszkiewicz M, Rymer W, et al. Treatment of essential thrombocythemia with anagrelide is associated with an increased risk of worsened kidney function [J]. Pharmacology, 2021, 106(5-6): 316-322.
|
[22] |
Landgren O, Goldin LR, Kristinsson SY, et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden [J]. Blood, 2008, 112(6): 2199-2204.
|